The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Disc Medicine Inc. IRON on Wednesday shared initial results from the company’s RESTORE-PV Phase 2 update. Initial RESTORE-PV ...
Disc Medicine announces positive updates on bitopertin, DISC-0974, and DISC-3405, with plans for upcoming clinical trials and data presentations. Disc Medicine, Inc. recently provided positive updates ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
DISC-0974: DISC-0974+Ruxolitinib Mouse Model: Wild-type mice were randomized to receive doses of placebo, ruxolitinib, DBIO-100, or a combination of ruxolitinib and DBIO-100. Results showed: ...
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, John Quisel, CEO. Please go ahead. Good morning, and welcome to the ...
In addition to Dr. Phillips’s presentation of the five-year IDE trial data, Dr. Avinash Patwardhan, Director of the Musculoskeletal Biomechanics Laboratory at Edward Hines Jr. VA Hospital will present ...
Disc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results